PTC Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $360.52Mn |
Net Profits | $83.5Mn |
Net Profit Margins | 23.16% |
PTC Therapeutics, Inc. Common Stock’s revenue jumped 101.55% since last year same period to $360.52Mn in the Q2 2026. On a quarterly growth basis, PTC Therapeutics, Inc. Common Stock has generated 32.28% jump in its revenue since last 3-months.
PTC Therapeutics, Inc. Common Stock’s net profit jumped 228.75% since last year same period to $83.5Mn in the Q2 2026. On a quarterly growth basis, PTC Therapeutics, Inc. Common Stock has generated 3072.45% jump in its net profits since last 3-months.
PTC Therapeutics, Inc. Common Stock’s net profit margin jumped 163.88% since last year same period to 23.16% in the Q2 2026. On a quarterly growth basis, PTC Therapeutics, Inc. Common Stock has generated 2347.16% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | 0.15 |
EPS Estimate Current Year | 0.15 |
PTC Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.15 - a 188.24% jump from last quarter’s estimates.
PTC Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 0.15.
Key Ratios
Earning Per Share (EPS) | 0.92 |
PTC Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 210.84% since last year same period to 0.92 in the Q2 2026. This indicates that the PTC Therapeutics, Inc. Common Stock has generated 210.84% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-07-30 | -0.17 | 0.92 | 641.18% |
2026-05-07 | -0.44 | -0.03 | 93.18% |
